Based on the network map, a key target, AKT1, was defined as the uppermost target, followed by IL6, PPARG, JUN, and EGFR, further verifying the significant role of the target against NAFLD. The gene discussed is IL6; the disease is metabolic dysfunction-associated steatotic liver disease.